Breaking News


Serum levels of transforming growth factor beta-1 in psoriasis patients: Effects of biological drugs


The levels of transforming growth factor beta-1 (TGF-beta-1) in patients with mild to moderate psoriasis vulgaris were investigated, in addition to its possible use as a biomarker in evaluating treatments with etanercept or efalizumab. Serum TGF-beta-1 levels were measured in 33 untreated patients (aged 24-77 years; P1 group) and in 7 of these patients before and 3 months after treatment with etanercept or efalizumab (P2 group). Nineteen healthy volunteers (aged 26-67 years) served as controls. The dose of efalizumab was 0.7 mg/kg s.c. initially, followed by 1 mg/kg s.c./week; etanercept was administered at 50 mg s.c./week. Significantly higher levels of TGF-beta-1 were found in the P1 group versus controls (P < ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list